PARP1 and PD-L1 dual-targeted bifunctional small-molecule inhibitors: a novel strategy for dual immunotherapy of triple-negative breast cancer
Abstract
ObjectivesCurrent single-agent PD-L1 immunotherapy and PARP inhibitor combination regimens have several drawbacks, including limited response rates, mismatched pharmacokinetics, and overlapping toxicities. This research aims to discover novel bifunctional small molecules that simultaneously block the PD-1/PD-L1 axis and PARP1, with prominent selectivity for PARP subtypes, to overcome bottlenecks in triple-negative breast cancer immunotherapy.MethodsComputer-aided molecular docking, 100 ns all-atom molecular dynamics simulation, homogeneous time-resolved fluorescence (HTRF) binding assay, biolayer interferometry (BLI), differential scanning fluorimetry (DSF), and PD-1/PD-L1 NFAT reporter cell assay were integrated to characterize dual-target lead molecules. A panel of eight PARP isoforms was tested to evaluate compound subtype selectivity.ResultsThe optimized molecule SP-1 potently disrupts the PD-1/PD-L1 protein-protein interaction (IC50 = 630 nM) and inhibits PARP1 at nanomolar levels (IC50 = 13 nM). Notably, SP-1 shows excellent PARP isoform selectivity: its inhibitory potency against PARP2 is nearly 18-fold weaker. At the same time, IC50 values for PARP3, PARP5a, PARP5b, PARP7, PARP8, and PARP10 all exceed 500 nM, greatly reducing the off-target risks associated with pan-PARP suppression. Orthogonal biophysical characterizations confirm that SP-1 directly binds to both PD-L1 and PARP1, forming stable intermolecular interactions. Cell-based functional assays demonstrate that SP-1 produces robust anti-tumor effects in MDA-MB-231 triple-negative breast cancer cells (IC50 = 1.01 μM) and markedly restrains tumor cell migration, invasion, and long-term clonogenic growth. Functional cellular assays further demonstrated that SP-1 effectively restored T cell function and enhanced T cell-mediated tumoricidal activity.ConclusionsSP-1 serves as a balanced dual-target inhibitor of PD-L1 and PARP1, with potent PARP1 subtype selectivity, which can be prioritized as a lead scaffold for developing novel dual-functional anti-breast cancer agents.
Related
- ''Threefold dual'' copper homeostasis regulation strategy: Targeted copper surge for enhanced cancer immunotherapy
- Precision targeting of tumor-associated macrophages via a 6-substituted pyrrolo[2,3-d]pyrimidine chimeric molecule for enhanced cancer immunotherapy
- Neuroprotectant development from small molecule inhibitors of CHOP/ATF4 expression
- Reversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase
- Targeted tumor desialylation by engineered probiotic reprograms the tumor microenvironment to potentiate immunotherapy
BibTeX
@article{du2026parp1,
title = {{PARP1 and PD-L1 dual-targeted bifunctional small-molecule inhibitors: a novel strategy for dual immunotherapy of triple-negative breast cancer}},
author = {Jing-Jing Du and Yixiang Fan and Xiaoyan Wu and Guang Zeng and Shengfeng Yuan and Yangbin Huang and Binbin Cheng},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1975588},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1975588},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - PARP1 and PD-L1 dual-targeted bifunctional small-molecule inhibitors: a novel strategy for dual immunotherapy of triple-negative breast cancer
AU - Jing-Jing Du
AU - Yixiang Fan
AU - Xiaoyan Wu
AU - Guang Zeng
AU - Shengfeng Yuan
AU - Yangbin Huang
AU - Binbin Cheng
PY - 2026
DA - 2026/11/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1975588
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1975588
AB - ObjectivesCurrent single-agent PD-L1 immunotherapy and PARP inhibitor combination regimens have several drawbacks, including limited response rates, mismatched pharmacokinetics, and overlapping toxicities. This research aims to discover novel bifunctional small molecules that simultaneously block the PD-1/PD-L1 axis and PARP1, with prominent selectivity for PARP subtypes, to overcome bottlenecks in triple-negative breast cancer immunotherapy.MethodsComputer-aided molecular docking, 100 ns all-atom molecular dynamics simulation, homogeneous time-resolved fluorescence (HTRF) binding assay, biolayer interferometry (BLI), differential scanning fluorimetry (DSF), and PD-1/PD-L1 NFAT reporter cell assay were integrated to characterize dual-target lead molecules. A panel of eight PARP isoforms was tested to evaluate compound subtype selectivity.ResultsThe optimized molecule SP-1 potently disrupts the PD-1/PD-L1 protein-protein interaction (IC50 = 630 nM) and inhibits PARP1 at nanomolar levels (IC50 = 13 nM). Notably, SP-1 shows excellent PARP isoform selectivity: its inhibitory potency against PARP2 is nearly 18-fold weaker. At the same time, IC50 values for PARP3, PARP5a, PARP5b, PARP7, PARP8, and PARP10 all exceed 500 nM, greatly reducing the off-target risks associated with pan-PARP suppression. Orthogonal biophysical characterizations confirm that SP-1 directly binds to both PD-L1 and PARP1, forming stable intermolecular interactions. Cell-based functional assays demonstrate that SP-1 produces robust anti-tumor effects in MDA-MB-231 triple-negative breast cancer cells (IC50 = 1.01 μM) and markedly restrains tumor cell migration, invasion, and long-term clonogenic growth. Functional cellular assays further demonstrated that SP-1 effectively restored T cell function and enhanced T cell-mediated tumoricidal activity.ConclusionsSP-1 serves as a balanced dual-target inhibitor of PD-L1 and PARP1, with potent PARP1 subtype selectivity, which can be prioritized as a lead scaffold for developing novel dual-functional anti-breast cancer agents.
SN - 1664-3224
ER -